Iconic Ventures

Iconic Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapeutics that target Tissue Factor (TF), a protein involved in inflammation, angiogenesis, and tumor growth. The company's lead program, ICON-1, is a first-in-class fusion protein designed to treat retinal diseases such as wet age-related macular degeneration (AMD) by addressing the underlying causes of vision loss. Iconic's pipeline also includes ICON-2 (XB002), a next-generation antibody-drug conjugate (ADC) for solid tumors, and ICON-4, a monoclonal antibody for ophthalmology. In 2022, the company was acquired by Endpoint Health to integrate its TF-targeting expertise into Endpoint's precision medicine platform.